Summary
This Phase 3 randomised controlled trial (IMvigor211) compared atezolizumab, a PD-L1 checkpoint inhibitor, with chemotherapy in patients with advanced or metastatic urothelial carcinoma who had progressed despite platinum-based treatment. The paper reports long-term follow-up data on overall survival and safety outcomes from this multicentre international trial. The findings contribute to evidence on immunotherapy efficacy and tolerability in this advanced cancer population.
UK applicability
As an oncology clinical trial, the findings are directly applicable to UK cancer treatment guidelines and NHS practice if atezolizumab is approved for this indication. However, this record is outside the scope of Vitagri's Pulse Brain, which focuses on farming systems, soil health, nutrient density, and food-related health outcomes.
Key measures
Overall survival, safety profile, adverse events
Outcomes reported
Long-term overall survival and safety outcomes in patients with platinum-treated locally advanced or metastatic urothelial carcinoma receiving atezolizumab versus chemotherapy.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.